[Use of Falicard and Sectral in patients with COPD and ischemic heart disease]

Vutr Boles. 1983;22(5):86-9.
[Article in Bulgarian]

Abstract

Thirty patients with chronic obstructive pulmonary disease (ChOPD) and concomitant ischemic heart disease (IHD) were studied that were admitted to the clinic for the treatment of a recurrence of the basic disease within the period 1981-1982. The patients were grouped into three groups of 10 patients and each group was treated for a period of 14 days, as follows: group 1--10 patients were given only sectral 50 mg per os during the first week and 10 mg/day during the second week; group II--treated with falicard, 5 mg daily, intravenously, for one week and later 2 X 5 mg, intravenously--the second week; group III, received sectral--50-100 mg/day after 5 mg falicard intravenously. Best results, manifested with a reduction of the paroxysms of dyspnea and stenocardia, were obtained in group III, suggesting the advantage of the combined effect with cardioselective beta-blockers and Ca-antagonists in the patients with ChOPD and concomitant IHD.

Publication types

  • English Abstract

MeSH terms

  • Angina Pectoris / drug therapy
  • Atenolol / administration & dosage
  • Atenolol / therapeutic use*
  • Coronary Disease / drug therapy*
  • Drug Evaluation
  • Drug Therapy, Combination
  • Humans
  • Lung Diseases, Obstructive / drug therapy*
  • Verapamil / administration & dosage
  • Verapamil / therapeutic use*

Substances

  • Atenolol
  • Verapamil